Development of an Image Analysis-Based Prognosis Score Using Google's Teachable Machine in Melanoma.

Google’s teachable machines artificial intelligence deep learning melanoma prognosis risk score

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
29 Apr 2022
Historique:
received: 04 04 2022
revised: 28 04 2022
accepted: 28 04 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 15 5 2022
Statut: epublish

Résumé

The increasing number of melanoma patients makes it necessary to establish new strategies for prognosis assessment to ensure follow-up care. Deep-learning-based image analysis of primary melanoma could be a future component of risk stratification. To develop a risk score for overall survival based on image analysis through artificial intelligence (AI) and validate it in a test cohort. Hematoxylin and eosin (H&E) stained sections of 831 melanomas, diagnosed from 2012-2015 were photographed and used to perform deep-learning-based group classification. For this purpose, the freely available software of Google's teachable machine was used. Five hundred patient sections were used as the training cohort, and 331 sections served as the test cohort. Using Google's Teachable Machine, a prognosis score for overall survival could be developed that achieved a statistically significant prognosis estimate with an AUC of 0.694 in a ROC analysis based solely on image sections of approximately 250 × 250 µm. The prognosis group "low-risk" ( The study supports the possibility of using deep learning-based classification systems for risk stratification in melanoma. The AI assessment used in this study provides a significant risk estimate in melanoma, but it does not considerably improve the existing risk classification based on the TNM classification.

Sections du résumé

BACKGROUND BACKGROUND
The increasing number of melanoma patients makes it necessary to establish new strategies for prognosis assessment to ensure follow-up care. Deep-learning-based image analysis of primary melanoma could be a future component of risk stratification.
OBJECTIVES OBJECTIVE
To develop a risk score for overall survival based on image analysis through artificial intelligence (AI) and validate it in a test cohort.
METHODS METHODS
Hematoxylin and eosin (H&E) stained sections of 831 melanomas, diagnosed from 2012-2015 were photographed and used to perform deep-learning-based group classification. For this purpose, the freely available software of Google's teachable machine was used. Five hundred patient sections were used as the training cohort, and 331 sections served as the test cohort.
RESULTS RESULTS
Using Google's Teachable Machine, a prognosis score for overall survival could be developed that achieved a statistically significant prognosis estimate with an AUC of 0.694 in a ROC analysis based solely on image sections of approximately 250 × 250 µm. The prognosis group "low-risk" (
CONCLUSIONS CONCLUSIONS
The study supports the possibility of using deep learning-based classification systems for risk stratification in melanoma. The AI assessment used in this study provides a significant risk estimate in melanoma, but it does not considerably improve the existing risk classification based on the TNM classification.

Identifiants

pubmed: 35565371
pii: cancers14092243
doi: 10.3390/cancers14092243
pmc: PMC9105888
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Med. 2019 Oct;25(10):1519-1525
pubmed: 31591589
Am J Surg Pathol. 2013 Jun;37(6):882-9
pubmed: 23629443
J Am Acad Dermatol. 2022 Mar;86(3):640-642
pubmed: 33581189
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
J Clin Oncol. 2007 Mar 1;25(7):869-75
pubmed: 17327608
J Pathol Inform. 2019 Feb 20;10:5
pubmed: 30972224
Arch Pathol Lab Med. 2020 Apr;144(4):500-522
pubmed: 32057276
Eur J Cancer. 2020 Jan;125:38-45
pubmed: 31838403
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Nature. 2021 Jun;594(7862):265-270
pubmed: 34040261
JAMA Netw Open. 2021 Sep 1;4(9):e2126337
pubmed: 34550383
Eur J Cancer. 2021 Jan;143:11-18
pubmed: 33278769
JCO Precis Oncol. 2020;4:319-334
pubmed: 32405608
Sci Rep. 2021 Feb 2;11(1):2809
pubmed: 33531581
Eur J Cancer. 2019 Sep;119:11-17
pubmed: 31401469
Eur J Cancer. 2019 Oct;120:114-121
pubmed: 31518967
Br J Dermatol. 2020 Mar;182(3):754-762
pubmed: 31017653
Eur J Cancer. 2020 Feb;126:141-158
pubmed: 31928887
Eur J Cancer. 2021 Sep;154:227-234
pubmed: 34298373
Eur J Cancer. 2019 May;113:47-54
pubmed: 30981091
Eur J Cancer. 2019 Jul;115:79-83
pubmed: 31129383
Clin Cancer Res. 2020 Mar 1;26(5):1126-1134
pubmed: 31636101
Clin Cancer Res. 2015 Jan 1;21(1):175-83
pubmed: 25564571
Eur J Cancer. 2019 Sep;118:91-96
pubmed: 31325876
Sci Rep. 2020 Feb 21;10(1):3217
pubmed: 32081956
JAMA Netw Open. 2019 Oct 2;2(10):e1913436
pubmed: 31617929
Clin Cancer Res. 2021 Jan 1;27(1):131-140
pubmed: 33208341
Eur J Cancer. 2018 Mar;92:108-118
pubmed: 29395684
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2030-2037
pubmed: 27401335
Surgery. 2018 Sep;164(3):589-593
pubmed: 29929753

Auteurs

Stephan Forchhammer (S)

Eberhardt Karls Universität, Universitäts-Hautklinik, 72076 Tübingen, Germany.

Amar Abu-Ghazaleh (A)

Eberhardt Karls Universität, Universitäts-Hautklinik, 72076 Tübingen, Germany.

Gisela Metzler (G)

Zentrum für Dermatohistologie und Oralpathologie Tübingen/Würzburg, 72072 Tübingen, Germany.

Claus Garbe (C)

Eberhardt Karls Universität, Universitäts-Hautklinik, 72076 Tübingen, Germany.

Thomas Eigentler (T)

Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Luisenstrasse 2, 10177 Berlin, Germany.

Classifications MeSH